标题：血清HE4、CA125联合检测对子宫内膜癌的诊断价值

      作者：陈燕娥，吴学明，陈绵
    (海口市妇幼保健院妇产科，海南 海口 570203)

      卷次： 2016年27卷7期

      【摘要】 目的 探讨人附睾分泌蛋白4 (HE4)、肿瘤标志物CA125联合检测对子宫内膜癌的诊断价值。方法 将
2014年10月至2015年4月我科收治的56例子宫内膜癌归为A组、65例子宫良性疾病为B组和60例健康体检者为对照
组，采用电化学发光免疫法和ELISA双抗夹心法分别检测三组受检者的血清HE4和CA125水平，并比较单项或两项联
合检测对子宫内膜癌的敏感性和特异性。结果 (1) A组患者的血清HE4和CA125水平分别为(75.22±3.12) pmol/L、
(32.98±3.28) U/mL，均明显高于 B组的(43.87±2.87) pmol/L、(17.64±2.04) U/mL和对照组的(30.08±2.0) pmol/L、
(11.08±1.98) U/mL，差异均有统计学意义(P<0.05)，而B组和对照组的血清HE4、CA125水平比较差异均无统计
学意义(P>0.05)；(2)子宫内膜癌患者Ⅲ期的血清HE4和CA125水平较Ⅱ期和Ⅰ期显著升高(P<0.05)；HE4诊断
子宫内膜癌的敏感性和特异性分别为 41.07%、98.21%，CA125为 33.93%、89.29%，二者联合检测为 53.57%、
94.64%。结论 HE4和CA125均可作为子宫内膜癌检测标志物，且可作为子宫内膜癌肿瘤良恶性的辅助诊断及
鉴别指标，HE4联合CA125检测可提高诊断准确率。

      【关键词】 人附睾分泌蛋白4；子宫内膜癌；CA125；诊断；价值

      【中图分类号】 R737.33 【文献标识码】 A 【文章编号】 1003—6350（2016）07—1054—03


Clinical value of combined detection of HE4, CA125 in application of endometrial carcinoma.
CHEN Yan-e, WU
Xue-ming, CHEN Mian. Department of Obstetrics and Gynecology, Maternal and Child Health Hospital of Haikou, Haikou
570203, Hainan, CHINA

【Abstract】 Objective To discuss the value of combined detection of human epididymis secretory protein 4
(HE4), and tumor marker cancer antigen 125 (CA125) in the diagnosis of endometrial carcinoma. Methods From Oct.
2014 to Apr. 2015, 56 patients with endometrial carcinoma admitted in our hospital were selected as group A, and 65 pa-
tients with uterine benign disease were selected as group B. Sixty healthy subjects were enrolled as the control group.
Serum HE4 and CA125 levels were detected by electrochemical luminescence immunoassay (ECLIA) and double-anti-
body Sandwich ELISA. The sensitivity and specificity of separate or combined detection of the two indexes in the di-
agnostic value of endometrial carcinoma were evaluated. Results (1) The serum HE4 and CA125 levels in group A
[(75.22 ± 3.12) pmol/L, (32.98 ± 328) U/mL] were significantly higher than those in group B [(43.87 ± 2.87) pmol/L,
(17.64±2.04) U/mL and the control group [ (30.08±2.0) pmol/L, (11.08±1.98) U/mL], with statistically significant differ-
ences (P<0.05), and there were no statistically significant differences in the two indexes between group B and the control
group (P>0.05). (2) Serum HE4 and CA125 levels in patients with endometrial carcinoma of stage Ⅲ were significantly
higher than those in patients of stageⅡ and stageⅠ (P<0.05). The sensitivity and specificity of HE4 in the diagnosis of
endometrial cancer were 41.07% and 98.21%, and those of CA125 were 33.93% and 89.29%, respectively. The sensitivity
·论 著·
6350.2016.07.008